(P088) Nonadherence to NCCN Guidelines Negatively Impacts Survival in Early-Stage Squamous Cell Carcinoma of the Larynx

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

NCCN guidelines were not followed in 9.4% of patients with early-stage LSCC in 2011, because chemotherapy was added to their RT-based regimen. In these patients, the addition of chemotherapy reduced patient survival by 18%. These results indicate the importance of adherence to NCCN guidelines when prescribing RT-based regimens in the early-stage LSCC setting.

Chi-Hsiung Wang, PhD, Erik Liederbach, BS, Arif Shaikh, MD, Mihir K. Bhayani, MD; Center for Biomedical Research Informatics, Department of Surgery, Department of Radiation Oncology, Department of Head and Neck Surgery, NorthShore University HealthSystem

INTRODUCTION: Primary treatment for early-stage squamous cell carcinoma of the larynx (LSCC) is radiation therapy (RT) alone or larynx-preserving surgery per National Comprehensive Cancer Network (NCCN) guidelines. The guidelines do not recommend the addition of chemotherapy in this setting. We investigated the National Cancer Data Base (NCDB) to determine adherence to these guidelines and its effects on overall survival (OS).

METHODS: Utilizing the NCDB, we selected 34,461 stage I–IV LSCC patients treated with RT from 1998 to 2011. Patients who received primary surgery were excluded. Chi-square tests, logistic regression models, and Cox proportional hazards models were utilized for analyses.

RESULTS: In the cohort, there were 19,610 (56.9%) early-stage (stage I/II) LSCCs and 14,851 (43.1%) late-stage (stage III/IV) LSCCs; 1,634 (8.5%) early-stage LSCCs received chemotherapy (CRT), as did 11,468 (77.9%) of the late-stage patients, over the entire time period studied. For early-stage cancers, the proportion of patients receiving CRT increased from 3.3% in 1998 to 9.4% in 2011 (P < .001). For late-stage cancers, the proportion of patients receiving CRT increased from 55.2% in 1998 to 87.8% in 2011 (P < .001). In a multivariate model, patients with early-stage LSCC were significantly more likely to receive chemotherapy if patients were younger (aged < 50 yr), female, African American or Hispanic, treated at a community-based hospital, and living in the Middle Atlantic (NJ, NY, and PA) or East North Central (IL, IN MI, OH, and WI) regions of the United States. Survival analyses were restricted to 1998–2006, and patients had a median follow-up of 4.4 years (range: 1–13 yr). Early-stage LSCC patients receiving RT alone had superior 5-year unadjusted OS rates compared with CRT patients (64.3% vs 52.7%; P < .001). These results persisted after adjusting for patient, facility, and tumor characteristics; and patients with CRT had worse OS (hazard ratio [HR] = 1.18; 95% confidence interval [CI], 1.07–1.31; P < .001). Late-stage LSCC patients receiving CRT had superior 5-year unadjusted OS rates compared with patients treated with RT alone (42.6% vs 25.9%; P < .001), and after similar risk adjustment, patients with CRT had superior OS (HR = 0.69; 95% CI, 0.65–0.73; P < .001) compared with those who received RT alone.

CONCLUSION: NCCN guidelines were not followed in 9.4% of patients with early-stage LSCC in 2011, because chemotherapy was added to their RT-based regimen. In these patients, the addition of chemotherapy reduced patient survival by 18%. These results indicate the importance of adherence to NCCN guidelines when prescribing RT-based regimens in the early-stage LSCC setting.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content